Source comparison
Tesamorelin + Ipamorelin Blend: Sourcing vs Cost Comparison
| Supplier Category | Purity Range (HPLC) | Synthesis Method | Price per 5mg+5mg Vial | Certificate of Analysis | Batch Consistency | Professional Assessment ||—|—|—|—|—|—|| Research-Grade (503B-Registered) | 98–99.5% | SPPS with multi-stage purification | $28
This comparison does not assign a generated winner or score.
- | Supplier Category | Purity Range (HPLC) | Synthesis Method | Price per 5mg+5mg Vial | Certificate of Analysis | Batch Consistency | Professional Assessment ||—|—|—|—|—|—|| Research-Grade (503B-Registered) | 98–99.5% | SPPS with multi-stage purification | $280–$320 | Third-party verified, published per batch | High. Lot-to-lot variability <2% | Worth the premium for replicable research. Contamination risk near zero, dose confidence high || Mid-Tier (State-Licensed Compounding) | 92–97% | SPPS with single-stage purification | $180–$240 | Supplier self-certified, available on request | Moderate. Lot-to-lot variability 3–7% | Viable for exploratory work. Risk of minor impurities, requires independent verification for publication-grade studies || Low-Cost (Unverified Overseas) | 85–92% | Liquid-phase or low-grade SPPS | $80–$140 | Often absent or fabricated | Low. Variability exceeds 10%, contamination frequent | False economy. Purity inconsistency makes results irreproducible, wasted tri
- The cost difference between a $140 vial and a $300 vial isn't peptide price. It's assurance that the compound matches the label. Unverified suppliers frequently substitute amino acid sequences, use incomplete purification that leaves deletion peptides in the final product, or mislabel peptide mass (claiming 5mg when the vial contains 3.2mg). Researchers using low-cost peptides without third-party verification aren't saving money. They're introducing uncontrolled variables that invalidate results. A single failed study due to contaminated peptides costs more in lost time and material than sourcing verified compounds from the start.